Bio-Techne Corporation

TECH · NASDAQ · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net — – — 1 disclosure · 1 bought / 0 sold · last Mar 23, 2026
Robert Bresnahan R · HOUSE · PA	−$14K – $14K −$21K – $15K today 2 filings · last Apr 8, 2025
April McClain Delaney D · HOUSE · MD	−$85K – $69K −$113K – $86K today 11 filings · last Apr 8, 2026
Ro Khanna D · HOUSE · CA	−$213K – $165K −$217K – $197K today 27 filings · last Jun 30, 2026

Recent transactions

Trades from May 10, 2022 – Jun 30, 2026

Politician	Type	Filed after	Amount
Ro Khanna D · HOUSE · CA-17	Sell	6 days Jun 30, 2026 → Jul 6, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	34 days Jun 2, 2026 → Jul 6, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	25 days May 15, 2026 → Jun 9, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	51 days Mar 23, 2026 → May 13, 2026	≥$15K
Ro Khanna D · HOUSE · CA-17	Sell	28 days Apr 13, 2026 → May 11, 2026	≥$1K
April McClain Delaney D · HOUSE · MD-6	Sell	28 days Apr 8, 2026 → May 6, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	8 days Mar 30, 2026 → Apr 7, 2026	≥$1K
April McClain Delaney D · HOUSE · MD-6	Sell	11 days Mar 26, 2026 → Apr 6, 2026	≥$1K
April McClain Delaney D · HOUSE · MD-6	Sell	14 days Feb 24, 2026 → Mar 10, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Buy	8 days Jan 29, 2026 → Feb 6, 2026	≥$1K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

615

13F shares

176.9M

Total invested

$12.5B

Ownership

113.4%

New positions

133

Closed positions

120

Increased positions

297

Reduced positions

242

Put/Call ratio

0.10

Holder	Reported	Shares	Value	Δ Qtr
BLACKROCK, INC.	8/7/2026	14M	$990.9M	+14.36%
FMR LLC	8/13/2026	12.8M	$904.0M	+61.96%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	10.2M	$721.9M	+0.38%
GOLDMAN SACHS GROUP INC	8/14/2026	7.3M	$518.8M	+277.83%
HBK INVESTMENTS L P	9/16/2026	6.8M	$482.2M	—
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	6.5M	$459.7M	+0.40%
MORGAN STANLEY	8/13/2026	6.4M	$450.4M	−25.29%
STATE STREET CORP	9/22/2026	6M	$422.5M	+1.91%
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	5.4M	$377.5M	+4.68%
INVESCO LTD.	8/14/2026	5M	$352.3M	+8.67%
RUANE, CUNNIFF & GOLDFARB L.P.	8/14/2026	3.3M	$236.6M	−1.27%
SNYDER CAPITAL MANAGEMENT L P	8/13/2026	3.2M	$223.5M	+68.08%
NEUBERGER BERMAN GROUP LLC	8/13/2026	2.8M	$201.0M	−14.85%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	8/3/2026	2.7M	$194.0M	−26.43%
MAIRS & POWER INC	8/14/2026	2.7M	$190.8M	−1.80%
CAPITAL RESEARCH GLOBAL INVESTORS	8/12/2026	2.6M	$185.2M	−17.76%
UBS GROUP AG	8/13/2026	2.5M	$175.1M	−18.85%
DIMENSIONAL FUND ADVISORS LP	8/11/2026	2.3M	$159.2M	+14.21%
WHITEBOX ADVISORS LLC	8/14/2026	2.1M	$148.4M	—
SUMITOMO MITSUI TRUST GROUP, INC.	7/30/2026	2.1M	$146.1M	+0.63%
JPMORGAN CHASE & CO	8/12/2026	1.9M	$132.6M	+81.72%
AMUNDI	8/11/2026	1.8M	$129.1M	+2426.78%
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.	8/14/2026	1.6M	$114.6M	—
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	8/14/2026	1.6M	$114.6M	−0.86%
MAVERICK CAPITAL LTD	8/14/2026	1.5M	$108.5M	−67.60%

Insider transactions

Insider	Type	Transacted	Price	Date
Higgins John L	M-EXEMPT	15.9K	$25.30	Sep 28
Higgins John L	F-INKIND	5.6K	$72.51	Sep 28
Higgins John L	M-EXEMPT	15.9K	—	Sep 28
Baumgartner Robert V	F-INKIND	5.6K	$72.55	Sep 22
Baumgartner Robert V	M-EXEMPT	15.9K	—	Sep 22
Baumgartner Robert V	M-EXEMPT	15.9K	$25.30	Sep 22
Crouse Steven C.	A-AWARD	14.1K	—	Aug 17
Crouse Steven C.	A-AWARD	8.7K	—	Aug 17
Geist William	A-AWARD	24K	—	Aug 17
Herr Amy E.	A-AWARD	1.4K	—	Aug 17

Analyst consensus

Hold26 analysts

Bearish · 0 · Hold · 14 · Bullish · 12

Earnings history

	EPS	Estimate
Q1 2025	$0.42	$0.38	Beat
Q2 2025	$0.42	$0.39	Beat
Q3 2025	$0.56	$0.51	Beat
Q4 2025	$0.53	$0.50	Beat
Q1 2026	$0.42	$0.42	Match
Q2 2026	$0.46	$0.43	Beat
Q3 2026	$0.53	$0.55	Miss
Q4 2026	$0.52	$0.52	Match

Peers

Company overview

IPO dateFeb 9, 1989

CEOKim Kelderman

Employees3,000

SectorHealthcare

IndustryBiotechnology

CountryUS

ExchangeNASDAQ

Websitewww.bio-techne.com

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.